Can We Use DAPT for 3 Months in Acute Coronary Syndrome?

Current guidelines recommend 12-month dual antiplatelet therapy (DAPT) after DES stenting for acute coronary syndrome (ACS) because of elevated MACE risk. 

¿Podemos utilizar DAPT durante 3 meses en síndromes coronarios agudos?

The development of more modern stents, with thin and ultrathin struts, compared against prior versions, has resulted in more effective devices in terms of stent thrombosis and restenosis. 

Prolonged DAPT has been associated with more bleeding, especially digestive. 

At present, there is evidence (from randomized studies and registries) to support the use of short term DAPT (1-3 months) to reduce bleeding. However, it has not yet been adopted after DES stenting for both acute and chronic coronary syndrome. 

This meta-analysis included 5 randomized studies (REDUCE, RESET‐ACS, SMART‐CHOICE, TICO and TWILIGHT‐ACS) with a total 16781 patients. 8387 receiving 3-month DAPT (49.97%) and receiving 8394 12-month DAPT.

Read also: Invasive Myocardial Viability Indexes.

The groups were similar.

There were no differences between the strategies in MACE (RR: 0.92; 95% CI: 0.76–1.11), cardiovascular mortality (RR: 1.26; 95% CI: 0.38–4.17), all-cause mortality (RR: 0.92; 95% CI: 0.48–1.77), MI (RR: 0.98; 95% CI: 0.74–1.30) or stent thrombosis (RR: 1.30; 95% CI: 0.55–3.05).

3-month DAPT presented a significant reduction of major bleeding vs 12-month DAPT (RR: 0.53; 95% CI: 0.43–0.64).

Conclusion

In ACS patients undergoing DES stenting, 3-month DAPT reduces bleeding risk with no increase of other complications. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the editorial board of SOLACI.org.

Original Title: Three versus 12‐month dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta‐analysis of randomized controlled trials.

Reference: Vijairam Selvaraj, et al. Catheter Cardiovasc Interv. 2022;100:1151–1158.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...